A simple precise, rapid accurate and sensitive non-aqueous potentiometric titration method was developed for quantitative determination of favipiravir from pharmaceutical dosage form. The titration was carried out using standardized 0.1 N perchloric acid. The proposed method was found to be precise with % RSD <1 (n = 6). The method showed strict linearity (r2 > 0.9999) between 10 % to 50 % w/v of 0.200 mg of drug substance weight. The percentage recovery of favipiravir in the optimized method was between 99.65 to 100.08 %. The method is also found to be rugged when checked by different analysts and using different lots of reagents and different makes of titrators.
Cite this article:
Rele Rajan V., Tiwatane Prathamesh P. A Validated Potentiometric Titration Method for Quantitative Determination of Favipiravir from Pharmaceutical Preparation. Asian Journal of Research in Chemistry. 2022; 15(1):49-1. doi: 10.52711/0974-4150.2022.00007
Rele Rajan V., Tiwatane Prathamesh P. A Validated Potentiometric Titration Method for Quantitative Determination of Favipiravir from Pharmaceutical Preparation. Asian Journal of Research in Chemistry. 2022; 15(1):49-1. doi: 10.52711/0974-4150.2022.00007 Available on: https://ajrconline.org/AbstractView.aspx?PID=2022-15-1-7
1. Sohrabi, C., Alsafi, Z.; O’Neill, N.; Khan, M.; Kerwan, A.; Al-Jabir, A.;et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19), Int. J. Surg., 76;2020:, 71–76.
2. Zhu, R. F.; Gao, R. I.; Robert, S. H.; Gao, J. P.; Yang, S. G.; Zhu, C.Systematic review of the registered clinical trials of coronavirus diseases 2019 (COVID-19), J. Transl. Med. 18;2020: 274–279.
3. Prajapat, M.; Sarma, P.; Shekhar, N.; Avti, P.; Sinha, S.; Kaur, H.; et al. Drug targets for corona virus: A systematic review. Indian J. Pharm. 52(1); 2020: 56–63.
4. Dong, L.; Hu, S.; Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther. 14(1);2020: 58–60.
5. De Clercq, E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chem.–Asian Journal. 14(22) ; 2019: 3962–3968.
6. Delang, L.; Abdelnabi, R.; Neyts, J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Research. 153;2018: 85–94.
7. Chen, C.; Huang, J.; Cheng, Z.; Wu, J.; Chen, S.; Zhang, Y.; et al. Favipiravir versus arbidol for COVID-19: A randomized clinical trial, medRxiv. 3; 2020: 17–20.
8. Ibrahim Bulduk, HPLC-UV method for quantification of favipiravir in pharmaceutical Formulations, Acta Chromatographica 2020:1-7 DOI: 10.1556/1326.2020.00828.
9. R. Suzuki, Y. Osaka, Quantitative Analysis of Favipiravir Spiked in Plasma Using by HPLC, Shimadzu excellence in science, application news no L 570, http://www.shimadzu.com/about/trademarks/index.html.
10. China patent. A kind of Favipiravir has the HPLC assay method of related substance. 21.09.2016. (CN104914185B)
11. China patent HPLC method for measuring related substances in Favipiravir. 16.09.2015. (CN104914185A).
12. Rele Rajan V. Tiwatane Prathamesh P. Determination of Favipiravir from Pharmaceutical Dosage Form by Extractive Ion Pair Complex Colorimetric Method, Asian Journal of Chemistry, 14(5);2021:321-323